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ABSTRACT
Background and objectives Obtaining consistent
efficacy beyond 12–24 hours with local anesthetics,
including extended-release formulations, has been
a challenging goal. Inflammation resulting from
surgery lowers the pH of affected tissues, reducing
neuronal penetration of local anesthetics. HTX-011, an
investigational, nonopioid, extended-release dual-acting
local anesthetic combining bupivacaine and low-dose
meloxicam, was developed to reduce postsurgical pain
through 72 hours using novel extended-release polymer
technology. Preclinical studies and a phase II clinical trial
were conducted to confirm the mechanism of action of
HTX-011.
Methods In a validated postoperative pain pig model
and a phase II bunionectomy trial, the analgesic effects
of HTX-011, oral meloxicam (preclinical only), liposomal
bupivacaine (preclinical only) and saline placebo were
evaluated. The optimal meloxicam:bupivacaine ratio for
HTX-011 and the effect of HTX-011 on incisional tissue
pH were also evaluated preclinically.
Results Preclinical data demonstrate the ability
of HTX-011 to address local tissue inflammation as
demonstrated by a less acidic tissue pH, which was
associated with potentiated and prolonged analgesic
activity. In the phase II bunionectomy study, HTX-011
achieved superior and sustained pain relief through 72
hours after surgery compared with each component in
the polymer.
Conclusions Preclinical animal and clinical results
confirm that the low-dose meloxicam in HTX-011
normalizes the local pH in the incision, resulting in
superior and synergistic analgesic activity compared
with extended-release bupivacaine. HTX-011 represents
an extended-release local anesthetic with a dual-acting
mechanism of action that may provide an important
advancement in the treatment of postoperative pain.
Trial registration number NCT02762929.

Introduction

© American Society of Regional
Anesthesia & Pain Medicine
2020. Re-use permitted under
CC BY-NC. No commercial
re-use. Published by BMJ.
To cite: Ottoboni T,
Quart B, Pawasauskas J,
et al. Reg Anesth Pain Med
2020;45:117–123.

The management of acute postoperative pain
continues to pose a significant challenge to clinicians
across all surgical specialties, with the most severe
pain after surgery occurring in the first 72 hours.1
Despite the administration of opioid and nonopioid
analgesics during this timeframe, most patients
still report that their pain is poorly managed.2 The
use of opioids is associated with an increased risk
of opioid-
related adverse events such as nausea,

vomiting, respiratory depression and sedation.
Along with uncontrolled pain, these adverse events
have been shown to contribute directly to increased
length of hospital stay and medical costs.3 More
effective nonopioid analgesics are needed to reduce
overreliance on opioids when managing postoperative pain and limit risks of abuse, addiction and
diversion.
Local anesthetics represent an important alternative to the use of systemic opioids, with bupivacaine hydrochloride (HCl), an immediate-release
amide-type anesthetic, as the most widely used for
addressing postoperative pain.4 However, bupivacaine HCl has a limited duration of action (≤12
hours). Recent attempts to extend the delivery of
bupivacaine HCl by using extended-
release (ER)
technology have failed to demonstrate consistent
clinical activity beyond 24 hours despite evidence of
extended drug release by prolonged plasma concentrations.5 The decreased activity of local anesthetics
in the presence of inflammation is a well-described
phenomenon.6 Increased tissue acidity caused by
the normal inflammatory process from injury, infection or surgical intervention reduces the penetration
of local anesthetics (both amide and ester classes)
such as bupivacaine into nerve cells in the affected
area,6 leading to diminishing analgesia beginning
in the first few hours and lasting for several days
(figure 1). In addition, inflammatory mediators can
also directly act on nociceptors, leading to peripheral sensitization that can further contribute to
reduced local anesthetic activity.7
HTX-011 is an investigational, ER, fixed-dose,
dual-acting local anesthetic that contains two active
ingredients, bupivacaine and low-dose meloxicam.
Meloxicam was included to reduce the local inflammatory response to tissue injury from surgery in
order to maintain physiologic pH in the microenvironment at the surgical site and reduce cytokine-
induced peripheral sensitization. To achieve an
ER profile for both bupivacaine and meloxicam,
HTX-011 uses a novel polymer technology,8 which
provides simultaneous diffusion of the active ingredients in a controlled manner over 72 hours. Since
the polymer formulation is somewhat viscous
and hydrophilic, HTX-011 can be applied to the
affected tissue in the surgical incision without a
needle and remains where it is placed, releasing
both drugs simultaneously through 72 hours.
Here, we present results from a preclinical postoperative pain model in pigs demonstrating that the
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bupivacaine alone (HTX-002) and meloxicam alone (HTX-009)
were compared with HTX-011.

Preclinical

This study was performed following approval of an application
form submitted to the Committee for Ethical Conduct in the
Care and Use of Laboratory Animals.

Postoperative pain model

Figure 1 Mechanism of bupivacaine penetration into the nerve. BPV,
bupivacaine.
incorporation of meloxicam in combination with bupivacaine in
an ER formulation synergistically potentiates the activity of bupivacaine for 72 hours. These findings were evaluated in a phase
II clinical study in bunionectomy that confirmed the synergistic
mechanism of action of HTX-011.

Methods
Extended-release polymer formulations

Initial preclinical studies were conducted using polymer formulations with a 144-hour (6-day) drug release profile (table 1).
Liposomal bupivacaine (EXPAREL, Pacira Bioscience, Parsippany, New Jersey, USA) and saline placebo were used as positive
and negative controls. Once the impact of local inflammation
on the analgesic activity of ER bupivacaine formulations and the
mitigating effect of meloxicam on the activity of bupivacaine was
recognized, formulations were optimized to provide a 72-hour
(3‑day) release profile to address the period after surgery known
to be most painful.1 For the purposes of comparing the combination to individual active ingredients, comparable ER formulations containing either bupivacaine alone or meloxicam alone
were also prepared. Finally, multiple formulations of bupivacaine plus meloxicam with varying ratios were prepared and
evaluated, resulting in the identification of the final composition
of HTX-011. In the clinical studies, polymer formulations of

An established animal model of postoperative pain in pigs was
used to evaluate the ability of meloxicam to suppress surgery-
induced local inflammation and normalize tissue pH, in order
to potentiate the analgesic activity of bupivacaine.9 Pigs are used
in the model because of their similarities to humans—they have
similar innervation patterns of their skin and their pain response
is predictive of pain measures observed in postoperative
patients. The study drug (1.8–3.4 mL depending on the formulated concentrations of active ingredients) was administered in
each treatment group (n=4) subcutaneously into the margins of
a 3-cm incision made into the pig flank to produce incisional
pain similar to that of a surgical procedure (online supplementary figure 1). Evaluation of pain was conducted as described
in Castel.9 Briefly, the intact side (contralateral to the incised
side) was tested first as a control measure. Von Frey filaments
(1–60 g) were applied approximately 0.5 cm proximal to the skin
incision three times with intervals of 5–10 s. If withdrawal by
the animal from the stimulus did not occur, a thicker filament
was applied, but if withdrawal occurred, a thinner filament was
applied. Greater force to elicit a withdrawal response implies
less nociceptive sensitivity, which was considered to be due to
greater analgesia from the test formulation. Postoperative pain,
as assessed by von Frey filament testing, was reported as the
force required to elicit a withdrawal response. Von Frey filament
testing was administered at baseline and at 1, 3, 5, 24, 48, and
72 hours postdose (assessments at 96, 120, and 144 hours postdose were included for the evaluations of the early 6-day release
formulations).

Investigation of meloxicam/bupivacaine ratios

Polymer fixed-combination formulations with ratios of melox
icam to bupivacaine ranging from 0 to 0.06 were prepared and
evaluated in pigs to identify the minimum ratio for clinical use.
The log of the average von Frey withdrawal force over 24–72
hours values was plotted against the meloxicam/bupivacaine
ratio and fit to a sigmoidal Emax model. The final, optimized
formulation of the combination was designated HTX-011.

Evaluation of meloxicam site of action

Table 1

Preclinical treatments

Treatment

Duration
of release
(days)

Bupivacaine
concentration
(mg/mL)

Meloxicam
concentration
(mg/mL)

Preclinical
dose
(mL)
1.8

ER-B-6D

6

176

0

ER-B/M-6D

6

176

35

1.8

ER-B-3D

3

29

0

3.4

ER-M-3D

3

0

1.8

1.8

ER-B/M-3D

3

29

1.8

3.4

Normal saline

N/A

N/A

N/A

1.8

Liposomal
bupivacaine

3

13

0

8.0

3D, 3-day formulation; 6D, 6-day formulation; B, bupivacaine; ER, extended release;
M, meloxicam; N/A, not applicable.

118

To investigate if the effect of meloxicam was locally mediated
or systemically mediated, an additional group of pigs (n=4) was
administered a 3-day release ER bupivacaine formulation (ER-B-
3D; table 1) plus a supratherapeutic dose (twice the maximum
approved human dose) of oral meloxicam (Loxicom Oral
Suspension, Norbrook, Overland Park, Kansas, USA) 0.5 mg/kg
once daily on days 1 through 6.

Effect of HTX-011 on local pH

The effect of HTX-011 on the pH of the tissues at the surgical
incision was also evaluated in the same pig postoperative pain
model to confirm the underlying mechanism of action. Incisions were made on the left and right flank of each of 4 pigs.
The left flank was treated with HTX-011 and the right flank
was left untreated (sham control). Tissue pH at the incision was
Ottoboni T, et al. Reg Anesth Pain Med 2020;45:117–123. doi:10.1136/rapm-2019-100714
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measured using needle pH electrodes (Microelectrodes, Bedford,
New Hampshire, USA) embedded into the subcutaneous tissues
for 48 hours.

Clinical

The safety and efficacy of HTX-011, matching polymer
formulations containing only bupivacaine (HTX-002) or only
meloxicam (HTX-009), and saline placebo (negative control)
were evaluated in a phase II bunionectomy study (ClinicalTrials.
gov: NCT02762929, registered May 2016). The study protocol
and all amendments were approved by a centralized institutional
review board (Western Institutional Review Board, Puyallup,
Washington, USA) and the initial protocol was also approved by a
local institutional review board (CHRISTUS Health IRB, Irving,
Texas, USA). All subjects provided written informed consent
prior to participation in any study-specific procedures. Inclusion and exclusion criteria are included in online supplementary
table 1. Eligible subjects underwent a unilateral simple Austin-
type bunionectomy under regional anesthesia with no more than
20 mL of 1% lidocaine without epinephrine administered as a
Mayo block. For the purposes of comparing HTX-011 to its
individual components and the controls, subjects were randomly
assigned to receive a single dose by instillation into the wound
of one of the following: HTX-011 (120 mg bupivacaine/3.6 mg
meloxicam), HTX-002 (120 mg bupivacaine), HTX-009 (3.6 mg
meloxicam), or saline placebo.
All subjects were required to remain in the clinic for assessments for 72 hours postdose and received opioids as rescue medication for pain control as needed. Pain intensity was assessed
in each subject using an 11-point Numeric Rating Scale (NRS),
where 0 equals no pain and 10 equals worst pain imaginable, and
analyzed using the area under the curve (AUC) of pain intensity
scores for each interval. The AUC was analyzed using analysis of
variance. Endpoints for the study included AUC for pain intensity scores through the first 24, 48, and 72 hours postsurgery.
X-rays to evaluate bone healing were performed.

Results
Preclinical studies

A 6-day ER bupivacaine formulation, ER-B-6D, was first compared
with a positive control, liposomal bupivacaine, and a negative
control, saline placebo. Liposomal bupivacaine demonstrated
analgesic activity on day 1, but von Frey scores were similar to
those of saline by 48 hours (figure 2), consistent with published
clinical results.5 Administration of ER-
B-
6D resulted in greater

Figure 2 Analgesic effect of an ER bupivacaine/meloxicam
combination formulation (ER-B/M-6D) compared with an ER
bupivacaine formulation (ER-B-6D), liposomal bupivacaine, and saline
placebo in a pig postoperative pain model. ER, extended release.

analgesia, with a similar pattern of diminishing analgesia after 24
hours, reaching its nadir at 96 hours. There was a return of analgesic activity by 120 hours that further increased at 144 hours. As
the period of diminished activity of ER-B-6D coincided with the
expected time course of inflammation associated with tissue injury,
combinations of bupivacaine and a nonsteroidal anti-inflammatory
drug (NSAID) were evaluated with the goal of reducing local
inflammation at the surgical site in order to maintain analgesic
activity from 12 to 120 hours. Testing of a 6-day ER combination
formulation of bupivacaine and meloxicam, ER-B/M-6D, resulted
in a sustained analgesic effect that lasted from the time of administration through 144 hours (figure 2).
To assess the relative contributions of its components, the analgesic efficacy of a 3-day release formulation of bupivacaine and
meloxicam, ER-B/M-3D, was compared with identical formulations of the individual active ingredients, ER-B-3D and ER-M-
3D. ER-B/M-3D produced a substantially greater analgesic effect
and maintained it over a longer period than either ER-B-3D or
ER-M-3D (figure 3). ER-B-3D demonstrated moderate analgesia
during the first few hours after surgery but this decreased and
remained low from hour 5 through 72 as evidenced by lower
values in tolerated maximal force in von Frey fiber testing. By
contrast, from 24 hours and through 72 hours postdose, pigs
that received the ER-B/M-3D tolerated a greater maximal force
B-
3D
(40.3–60.0 g) compared with those that received ER-
(13.8–19.3 g) or saline placebo (1.1–3.4 g). ER-M-3D provided
almost no analgesia throughout the entire study period in these
animals.
The results observed with the ER-B/M-3D formulation led to
a follow-up study to determine whether the effect of meloxicam
on the activity of bupivacaine required local delivery or could
be achieved with systemic administration. In a group of pigs
receiving ER-
B-
3D and supratherapeutic daily doses of oral
meloxicam (n=4), von Frey fiber results were similar to those for
ER-B-3D alone, demonstrating that meloxicam must be administered locally in combination with bupivacaine to produce the
optimal effect (figure 3).
These results led to a full assessment to select the optimal
ratio of bupivacaine and meloxicam. The relationship between
the average von Frey withdrawal force and the meloxicam/bupivacaine ratio is presented in figure 4. The half-maximal effect
was at a meloxicam/bupivacaine ratio of 0.022. Administration
of formulations with a meloxicam/bupivacaine ratio of <0.030
generally resulted in a lower analgesic effect compared with
formulations with ratios of ≥0.030. Thus, the lowest effective meloxicam/bupivacaine ratio was determined to be 0.030,
and concentrations of 29 and 0.9 mg/mL of bupivacaine and
meloxicam, respectively, were selected for further development
in a formulation designated HTX-011.
To confirm the proposed mechanism of action, tissue pH at
the surgical incision was measured after administering HTX-011
into the margins of a surgical incision in pigs. In the pig model,
tissue pH at the site of incision with HTX-011 treatment was
consistently higher from 24 hours through 48 hours post-
incision compared with control (figure 5). The approximately
1 pH unit difference observed at 48 hours relates to substantially
more unionized bupivacaine available to enter the nerve with
HTX-011 treatment compared with control (7.5% unionized vs
0.6% unionized, respectively).

Clinical evaluation of HTX-011 and its components

In the phase II clinical study, 237 subjects undergoing bunionectomy were included in the assessment of the individual
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Figure 3 Analgesia from pig model after surgical incision through 72
hours following administration of ER bupivacaine plus meloxicam, ER
meloxicam, ER bupivacaine with and without oral meloxicam, or saline
placebo. ER, extended release.

Figure 5 pH of untreated or HTX-011-treated incisional tissue in pig
postoperative pain model. SE, standard error.

components; 74 received HTX-011, 30 received HTX-002, 30
received HTX-009, and 103 received saline placebo. Subject
characteristics were similar across the treatment groups; subjects
were predominately white women with a mean age of 50 years
(online supplementary table 2).
As shown in figure 6, subjects who received HTX-011 after
undergoing bunionectomy exhibited significantly lower pain
scores over the first 24, 48, and 72 hours (AUC0-24, AUC0-48, and
AUC0-72) than those who received ER formulations of bupivacaine alone (HTX-002), meloxicam alone (HTX-009), or saline
placebo. Pain curves for HTX-011 and HTX-002 separated
within the first 5 hours. Similar to the preclinical model, the
initial analgesic activity following administration of HTX-002
rapidly diminished and was comparable to placebo by 12 hours.
Clinical results with HTX-009 were also similar to the preclinical model and indistinguishable from saline placebo.
Although the study was not powered to detect a reduction
in opioid use between groups, HTX-011 significantly increased
the time to first opioid rescue and decreased opioid consumption compared with the HTX-009, HTX-002, and saline placebo
groups (table 2). The overall incidence of any adverse event
and the types of adverse events with HTX-011 were generally
comparable to or lower than those for HTX-002 and HTX-009.

Figure 4 Relationship between the average von Frey withdrawal force
and meloxicam:bupivacaine ratio.
120

Based on the X-ray results, there was no evidence of delays in
bone healing in any treatment group.

Discussion

Local anesthetics are used in most surgical procedures in the USA
for postoperative pain management; however, consistent activity
through the critical first 72 hours after surgery has been challenging. One barrier to developing a long-acting local anesthetic
for treating postoperative pain is the ability of the local anesthetic to remain active in the local inflammatory, acidified environment that occurs as a result of surgery.10 The hypothesis that
diminished local anesthetic response can be prevented by local
delivery of meloxicam to control inflammation is supported by
the results presented here. HTX-011 normalized tissue pH and
significantly improved analgesic activity and duration of analgesia compared with its individual components.

Causes for diminished local anesthetic activity

The inflammatory process following surgery-
associated tissue
injury initiates several changes in the local tissue environment.
The first action taken by the body immediately after tissue injury
is to control bleeding.11 Platelets activate as part of the coagulation cascade and as the clot forms, they release cytokines that
initiate the inflammatory response.12 Shortly after tissue injury,
inducible cyclo-oxygenase (COX)-2 is upregulated13 and initiates a cascade of events that results in synthesis of proinflammatory prostaglandins such as prostaglandin E2 (PGE2). Serotonin
released by platelets as well as the increasing concentrations of
PGE2 in the presence of bradykinin results in an increase in
local vascular permeability.14 This, coupled with the concentration gradient of chemotactic agents such as complement factors,
interleukin-1, tumor necrosis factor-α, transforming growth
factor p, and platelet factor 4, stimulates neutrophils to migrate
into the wound.15 In addition, inflammation leads initially to
a drop in pH due to local vasoconstriction and resulting ischemic conditions; later as a result of infiltration and activation of
neutrophils in the tissue,11 there is increased energy and oxygen
demand and accelerated glucose consumption via glycolysis.
These conditions result in increased lactic acid secretion,16 17
causing acidification.18 Therefore, the low tissue pH observed is
likely due to a combination of ischemia and activated leucocytes
consuming oxygen and releasing acid.
Local anesthetics bind to the sodium voltage-gated ion channels from the interior of the neuron via the ionized (protonated)
form. The pKa (pH where 50% of the molecules are unionized and 50% are ionized) of all local anesthetics is above the
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Figure 6 Mean pain intensity scores through 72 hours following administration of HTX-011, HTX-002, HTX-009, or saline placebo in phase II
bunionectomy study. AUC0-XX, area under the curve from 0 to XX number of hours. NRS, numeric rating scale; PBO, placebo; SE, standard error.
physiologic pH of 7.4. Therefore, when infiltrated into normal
tissue, the majority of local anesthetic molecules are in the
ionized state. However, in order to pass through the neuronal
membrane, local anesthetics must be unionized19; thus, only
a fraction of the local anesthetic molecules are able to pass
through the neuronal membrane (figure 1). Once the unionized
form enters the nerve, the equilibrium between unionized and
ionized is reestablished and ionized molecules are available to
bind to the voltage-gated ion channels.
Inflammation resulting from injury produces an acidic tissue
environment outside the nerve favoring the ionized form,
reducing the concentration of molecules available to penetrate
into the nerve. This effect may explain why even as recent
attempts to extend the delivery of local anesthetics have resulted
in prolonging exposure, they have not demonstrated consistent
pharmacodynamic activity beyond 24 hours.
An emerging line of evidence suggests that peripheral sensitization may also play a role in reducing the activity of local
anesthetics in the presence of inflammation. PGE2 is known to
act directly on C-fibers, resulting in a reduced action potential
threshold leading to peripheral sensitization.20 One pathway by
which this occurs is PGE2 binding to the EP class of receptors
on the surface of the nerve, ultimately resulting in upregulation
and increased excitability of tetrodotoxin-resistant ion channels,
some of which appear to have low sensitivity to inhibition by
local anesthetics.21 22

Table 2

Development of HTX-011
HTX-011 utilizes a novel fourth-generation tri(ethylene glycol)
poly(orthoester) (TEG-POE)-based formulation that is designed
for parenteral, sustained-release drug delivery applications.8
TEG-POE polymer formulations are semiviscous liquids that
control drug release via diffusion. The drug release rate from
these formulations can be adjusted to provide delivery over a
period of days to weeks by controlling the composition and
molecular weight of the TEG-POE as well as the selection of
biocompatible solvent excipients, such as the dimethyl sulfoxide
and glycerol triacetate used in HTX-011.23 Because drug release
is controlled by diffusion as opposed to polymer erosion used
in other ER systems, there is no delayed early phase release,
preventing the initial delivery of the active ingredient.23 Additionally, TEG-POE hydrolysis is slow during the delivery phase,
ensuring that the active ingredients diffuse at a consistent rate.
TEG-POE polymer is composed of repeating units containing
a diol connected to an orthoester. Once the active components
have been released from the formulation, the rate of polymer
hydrolysis rapidly increases via the cleavage of the orthoester
bonds, liberating small, water-soluble monomeric compounds
that are rapidly cleared from the body by the kidneys. These
compounds do not alter the pH of the local tissue environment.
The novel ER polymer is a component of the FDA-approved
SUSTOL (granisetron) ER injection for subcutaneous use and has

Opioid consumption by treatment group
HTX-011
120 mg/3.6 mg
(n=74)

Median time to first opioid rescue medication (hours)

10.63

 P value versus HTX-011

HTX-002
120 mg
(n=30)
6.31
0.0025

HTX-009
3.6 mg
(n=30)

Saline placebo
(n=103)

3.83

3.62

<0.0001

<0.0001

Total opioid use (mg)
0–24 hours
 Mean (SD)

8.55 (8.089)

 P value versus HTX-011

15.07 (7.987)
0.0003

16.07 (9.766)
0.0001

16.75 (8.820)
<0.0001

0–72 hours
 Mean (SD)

23.70 (19.145)

 P value versus HTX-011

29.40 (18.788)
0.1699

32.70 (20.742)
0.0365

32.65 (23.505)
0.0077

Total opioid use is expressed as intravenous milligram morphine equivalents (ie, morphine equivalents). P values from Wilcoxon test (time to first opioid use) and analysis of
variance (total opioid use).
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been extensively evaluated in nonclinical safety studies including
repeated-dose toxicity with daily dosing for 90 days, for in vitro
and in vivo genotoxicity, and for reproductive and developmental
toxicity studies in two species. Additional nonclinical toxicology
studies conducted during the development of HTX-011 revealed
no findings suggestive of systemic toxicity and no sustained local
effects. HTX-011 was also extensively evaluated in local tolerance studies; briefly, HTX-011 did not demonstrate an effect
that was meaningfully different compared with bupivacaine HCl
on bone healing, skin wound healing, wound healing in the presence of an implant (eg, mesh), or neurotoxicity (data on file).
Initial studies focused on the development of an ER bupivacaine
formulation. It is known that the analgesic activity of liposomal
bupivacaine diminishes after 24 hours,5 and it was hypothesized
that this could be due, in part, to the migration of the liposomes
away from the pain-generating area. If that is the case, a polymeric ER bupivacaine formulation administered directly to the
wound should remain in contact with pain-
generating tissue
and provide prolonged analgesia. A polymer-based, 6-day ER
formulation, ER-B-6D, produced superior activity but diminishing analgesia after 24 hours; however, an unexpected return
of analgesic activity was observed after 96 hours. This return of
activity after 96 hours negated the migration hypothesis but was
consistent with the expected time course of local inflammation
produced by surgical insult. The initial inflammatory response
with resulting drop in tissue pH6 and peripheral sensitization
subsides with time, with an increasing fraction of bupivacaine in
the unionized form available to penetrate the nerve membrane
producing a greater analgesic effect.
In theory, local administration of NSAIDs would be expected
to limit the local inflammatory response and inhibit the
production of tissue prostaglandins, thereby reducing the local
inflammatory-mediated tissue pH drop and peripheral sensitization. This could prevent the normal loss of clinical efficacy
beyond the 12- to 24-hour window seen with other ER local
anesthetics. Screening of various NSAIDs to be coformulated
with bupivacaine that may alter local inflammation led to the
selection of meloxicam. The combined formulation demonstrated sustained analgesic activity over 144 hours in the pig
postoperative pain model, which was not observed with ER
bupivacaine alone. In addition, the properties of meloxicam
made it ideally suited for inclusion into the formulation: high
potency (allowing for low concentrations and better control of
drug release), low COX-1 activity with a demonstrated minimal
impact on clotting, and low cardiovascular risk, especially given
the short duration and low systemic exposure associated with
local delivery.24–26 Notably, in the HTX-011 phase III studies
in bunionectomy and herniorrhaphy, mean maximum concentrations of meloxicam (Cmax) were much lower compared with
the mean maximum concentration of oral meloxicam using the
lowest recommended dose in a healthy male population (mean
meloxicam Cmax in phase III studies, 31.6 ng/mL and 181 ng/mL
[data on file]; Cmax in meloxicam package insert, 1050 ng/mL).27
The results of the assessment of bone healing conducted in the
phase II bunionectomy study (data on file) are consistent with
studies showing that short-term use of low-dose NSAIDs does
not interfere with bone healing.28 29

Demonstration of synergistic activity of bupivacaine
and meloxicam
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The usual isobologram analysis used to demonstrate synergy
requires both ingredients of the combination to have activity on
the measured response in order to generate dose-response curves
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for each individual active ingredient.30 As demonstrated in both
the pig postoperative pain model and in the phase II bunionectomy study, the meloxicam component of HTX-011 produced
no appreciable analgesic activity, whereas HTX-011 produced
significantly greater and prolonged analgesia than either bupivacaine or meloxicam separately. Therefore, the supra-additive
analgesic activity of HTX-011 over the ER bupivacaine formulation in the bunionectomy phase II study confirms a synergistic
interaction, with meloxicam potentiating the analgesic activity
of bupivacaine.
In both preclinical and clinical models, the enhanced analgesic
activity of formulations of bupivacaine plus meloxicam over
formulations of bupivacaine alone became apparent within the
first 5 hours; this was maintained over 72 hours, consistent with
the period where inflammation would be impacting the activity
of bupivacaine. This is also consistent with the meloxicam
component producing a direct effect on the microenvironment
of the surgical site, as high systemic concentrations of meloxicam
had no impact on the analgesic activity of bupivacaine. This may
be due to several factors, such as the need for high local concentrations to reduce inflammation in order to normalize the pH
and to limit peripheral sensitization, as well as local ischemia
resulting from surgery preventing systemic meloxicam from
achieving pharmacologically active concentrations in the tissue.
Further studies will be needed to establish the individual contributions of these effects, but the dramatic synergy resulting in
significantly increased analgesia is evident in both preclinical and
clinical studies.
In summary, HTX-011 is a nonopioid, ER, dual-acting local
dose
anesthetic formulation comprising bupivacaine and low-
meloxicam that uses novel, extended-
release polymer technology. Preclinical data demonstrate the ability of HTX-011 to
address local tissue inflammation by reducing the drop in tissue
pH in the incision after surgery compared with control, which
was associated with potentiated and prolonged analgesic activity.
The approximately 1 pH unit difference observed at 48 hours
results in >10-fold more unionized bupivacaine available to enter
the nerve with HTX-011 treatment compared with control. The
ability to provide consistent analgesia throughout the critical 72
hours postoperative period may provide an important option for
clinicians to manage pain without overreliance on opioids.
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